Company
Celcuity
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
2
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Revtorpyk approved NovelPriority reviewJul 14, 2026
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Pivotal-lookingRecruiting
Celcuity IncIndustry
NCT06757634 · 1,180 participants (planned) · Start Jul 24, 2025 · Primary completion Mar 31, 2029
Drug: Arm A: Gedatolisib + Palbociclib + Fulvestrant; Arm B: Ribociclib + Fulvestrant and 2 more · For: Breast Cancer
Sites: Jonesboro, Arkansas; Little Rock, Arkansas; Duarte, California · 239 sites in all
Marketed drugs (1)
Newest FDA action first.
- Revtorpyk Gedatolisib · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.